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Abstract The level of apoptosis in rectal carcinomas of
patients treated by surgery only predicts local failure; pa-
tients with intrinsically high-apoptotic tumors develop less
local recurrences than patients with low levels of apoptosis.
To identify genes involved in this intrinsic apoptotic pro-
cess in vivo, 47 rectal tumors with known apoptotic phe-
notype (24 low- and 23 high-apoptotic) were analyzed by
oligonucleotide microarray technology. We identiﬁed
several genes differentially expressed between low- and
high-apoptotic tumors. Unsupervised clustering of the tu-
mors based on expression levels of these genes separated
the low-apoptotic from the high-apoptotic tumors, indi-
cating a gene expression-dependent regulation. In addition,
this clustering revealed two subgroups of high-apoptotic
tumors. One high-apoptotic subgroup showed subtle dif-
ferences in mRNA and protein expression of the known
apoptotic regulators BAX, cIAP2 and ARC compared to
the low-apoptotic tumors. The other subgroup of high-
apoptotic tumors showed high expression of immune-re-
lated genes; predominantly HLA class II and chemokines,
but also HLA class I and interferon-inducible genes were
highly expressed. Immunohistochemistry revealed HLA-
DR expression in epithelial tumor cells in 70% of these
high-apoptotic tumors. The expression data suggest that
high levels of apoptosis in rectal carcinoma patients can be
the result of either slightly altered expression of known
pro- and anti-apoptotic genes or high expression of im-
mune-related genes.
Keywords Rectal cancer  Apoptosis  Gene expression
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Introduction
Apoptosis is an important intrinsic characteristic of rectal
tumors. High amounts of apoptotic tumor cells correlate
with a reduced local recurrence risk in rectal cancer pa-
tients who were treated by surgery only [1, 2]. From the
literature, it is known that the apoptotic process can be
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way and the mitochondrial pathway. The death-receptor
pathway is induced via engagement of death receptors,
such as CD95, by their ligands. Receptor polymerization
leads to the recruitment of the death-inducing signaling
complex, resulting in the activation of caspase-8. The
mitochondrial pathway is activated during cellular stress,
such as DNA damage or oxidative stress, via the release of
cytochrome c from the mitochondrion resulting in the
activation of caspase-9. This cytochrome c release is con-
trolled by the pro- and anti-apoptotic members of the Bcl-2
family.
Deregulation of these apoptotic pathways can contribute
to a number of human diseases, like neurodegenerative
disorders and cancer. During progression from normal cell
to tumor cell and consequent metastasis, the cells are ex-
posed to a range of apoptotic stresses. Cells that acquire
mutations that suppress apoptosis will have a selective
growth advantage and will expand. Such anti-apoptotic
mutations can therefore result in therapy-resistant tumors
and are thought to contribute to treatment failure. For rectal
cancer, several studies have evaluated the role of apoptosis
for the sensitivity of tumors to anti-cancer treatment. Tu-
mors with high levels of intrinsic apoptosis were indeed
more likely to regress upon neo-adjuvant radiochemother-
apy than tumors where apoptosis was low (reviewed by
Smith et al. [3]), indicating that these intrinsically high-
apoptotic tumors are more sensitive to apoptotic triggers.
Since this sensitivity can be regulated by the Bcl-2 family
of proteins, use of the pro-apoptotic Bax and the anti-
apoptotic Bcl-2 proteins as predictive markers for response
to neo-adjuvant therapy has been studied. Two recent
publications indeed suggest a role for Bax in therapy re-
sponse [4, 5], but most studies found no correlation be-
tween the expression of Bax or Bcl-2 and tumor
downstaging or clinical outcome of the patients after radio-
and/or chemotherapy [3].
Interestingly, rectal cancer patients treated only by sur-
gery had a relatively low local recurrence rate when the
tumor intrinsic level of apoptosis was high. Because this
intrinsic apoptosis occurred in the absence of neo-adjuvant
treatment, it is important to know which proteins are
responsible for the low or high levels of intrinsic apoptosis
in vivo. The objective of our study was therefore to identify
genes involved in the induction and/or progression of
intrinsic apoptosis in human tumors. Since the process of
apoptosis can be regulated by multiple proteins (pro- and
anti-apoptotic proteins) and at several levels in the path-
ways (up- and downstream of the mitochondria), identiﬁ-
cation of apoptosis regulators requires assessment of the
expression of a large number of genes. Oligonucleotide
microarray analysis allowed us to assess such large num-
bers of genes simultaneously. We used this technique to
analyze rectal tumors with known apoptotic phenotype,
available from a prospective multicenter trial with stan-
dardized surgery and pathologic examination [6], and
compared the expression proﬁles of low- versus high-
apoptotic tumors. The genome-wide information reported
here contributes to our understanding of apoptosis in vivo.
Materials and methods
Patients and tumor samples
Tumor samples were obtained at time of surgery from
rectal cancer patients participating in the Dutch TME trial
[6]. A total amount of 47 freshly frozen non-irradiated
tumors were selected with a clear distinction in their
apoptotic phenotype (lowest versus highest quartiles of
apoptosis levels) as previously determined by immuno-
histochemical staining with the M30 antibody [2]; 24 tu-
mors had low levels of apoptosis (< 5 M30-positive cells/
mm
2 tumor epithelium) and 23 tumors had high levels of
apoptosis (> 25 M30-positive cells/mm
2 tumor epithe-
lium). There was no signiﬁcant difference between these
low- and high-apoptotic tumors with respect to clinico-
pathologic characteristics such as gender, age, TNM stage
or tumor differentiation status.
RNA isolation and microarray procedure
RNA was extracted as described in detail elsewhere [2]
from macrodissected samples containing at least 60% tu-
mor epithelium, as determined by haematoxylin and eosin
(HE)-stained frozen sections. Quality of total RNA was
assessed with lab-on-a-chips on the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, California). All
samples were shown to be free of DNA contamination and
for each sample the ratio 28S/18S was > 1.5. Ampliﬁca-
tions of mRNA and dye couplings were performed using
Ambion’s Amino Allyl MessageAmp
TM kit and protocol
(Ambion Inc., Austin, TX). Per microarray experiment,
2.0-lg aliquots of RNA were ampliﬁed, and 5.0-lg aliqu-
ots of amino allyl-labeled aRNA was coupled to CyDye
Post Labelling Reactive Dyes (Ambion Inc.): Cy5 for tu-
mor samples, and Cy3 for reference sample, consisting of
pooled RNAs isolated from ﬁve normal rectum samples
and ﬁve colorectal cancer cell lines (HCT116, LS411N,
SW480, HCT15 and Caco2).
Oligonucleotide microarrays
About 2.0-lg aliquots of labeled sample RNA were mixed
with equal amounts of labeled reference RNA and frag-
mented using RNA Fragmentation Reagents and protocol
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Carlsbad, CA) and 20 lg polyadenylic acid (Sigma–Al-
drich, St. Louis, MO) were added and mixtures were heated
at 100 C for 1 min, placed on ice for 2 min and at 42 C for
5 min. Preheated 2 · hybridization buffer (50% formam-
ide, 10 · SSC, 0.01% SDS) was added just before
hybridization at 42 C o/n onto the Human Genome Oligo
Set Version 3.0 arrays, manufactured at the Central
Microarray Facility (CMF) of the Netherlands Cancer
Institute. Information about this oligo set (e.g. oligonu-
cleotide sequence, gene symbol, protein description, En-
sembleID and GO-term) is available at the website of
Operon (http://www.omad.operon.com). Protocols, Ge-
neID list and information about arrays are available at the
website of the CMF (http://www.microarrays.nki.nl). Of
each slide, two images were scanned using the Agilent
G2565BA Microarray Scanner (Agilent Technologies), at
50 and 100% gain intensities. Spot intensities were ex-
tracted from the scanned images with Genepix 5.1 (Axon,
Baden, Switzerland). Spots with aberrant shapes were
ﬂagged by the software and checked manually.
Computational and statistical analysis
Raw intensity data (.gpr ﬁles) were directly loaded into the
R environment (http://www.r-project.org). For normaliza-
tion of the arrays and identiﬁcation of differentially ex-
pressed genes, the Limma (linear models for microarray
data) package of Bioconductor (http://www.bioconduc-
tor.org) was applied. Control spots and spots with more
than 10% saturation, a diameter smaller than 60 lmo r
signal intensity less than 150 above background were ex-
cluded from the analyses. Data were corrected for local
background (method normexp) and normalized within ar-
rays and between arrays (method quantile). The spots of the
low and high intensity scans were normalized separately.
Duplicate experiments were done for 10 different tumor
samples, showing Pearson correlation coefﬁcients ranging
from 0.86 to 0.92.
Statistically signiﬁcant differences in the staining of the
oligos were assessed using a moderate empirical Bayes test
statistics [7] available through the Limma software pack-
age. The B-value is the log-odds that a gene is differently
expressed. The obtained p-values were corrected for mul-
tiple testing using the False Discovery Rate method [8].
Oligos with B-values ‡0.5 and corrected p-values £0.05
were considered statistically signiﬁcant. These oligos were
grouped into biological categories using the Gene Ontol-
ogy (GO) terms provided by the manufacturer.
Unsupervised hierarchical clustering (with ‘unweighted
average’ and ‘correlation’) was done with Spotﬁre Deci-
sionsite
TM (Somerville, MA, USA) using the normalized
log2 Cy3/Cy5-data.
The Gene Ontology Tree Machine (GOTM; http://
www.genereg.ornl.gov/gotm) tool was used to identify
biological processes that were signiﬁcantly over-repre-
sented among the oligos found to be differentially ex-
pressed when compared with the list of all oligos on the
array [9]. For these GOTM-analyses we used the Ensem-
bleIDs corresponding to the oligonucleotide sequences on
the array as gene identiﬁers.
Quantitative RT-PCR (qPCR)
For ﬁrst strand cDNA synthesis, 1.5-lg aliquots of total
RNA were reverse transcribed using oligo(dT)-primers and
M-MLV Reverse Transcriptase (Promega Corporation, WI,
USA), according to manufacturer’s instructions. Total
RNA was available from 35 tumor samples that were
analyzed by microarray analysis.
The real-time PCR primer sets were designed by Su-
perArray (SuperArray Bioscience Corporation, MD, USA).
Real-time ampliﬁcations were done according to manu-
facturer’s protocol using RT
2 Real-Time
TM SYBR Green/
Fluorescein PCR Master Mix (SuperArray Bioscience
Corporation). Reactions were run on an iCycler iQ Real-
time Detection System (Bio-Rad Laboratories, CA, USA).
A melt curve was generated at the end of each run in order
to determine the speciﬁcity of the product. A calibration
curve, consisting of several dilutions of cDNA of the ref-
erence used for the microarray procedure, was included for
each gene to allow calculation of the relative starting
quantities. These relative starting quantities were used in
the normalization and statistical analyses.
Expression levels were normalized to three genes
(CPSF6, GAPDH and HPRT1) to acquire a reliable nor-
malization of the qPCR data. These genes showed the least
variation between all samples as determined by the geN-
orm programme [10]. This geNorm method provides a
normalization factor per gene, representative of the amount
of mRNA in each sample.
To compare the qPCR data with the microarray data, the
qPCR data were log2 transformed and Pearson correlation
coefﬁcients were determined using SPSS statistical soft-
ware (version 12.0 for Windows, SPSS, Inc., Chicago, IL).
Immunohistochemisty
Stainings were performed on 4-lm sections using the fol-
lowing antibodies: anti-Bax (N-20) at 1:200 (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-cIAP2 (AF817) at
1:200 (R&D Systems, Minneapolis, MN), anti-ARC (CT)
at 1:2,000 (ProSci Inc., Poway, CA), anti-HLA-A (HCA2)
at 1:100 (kindly provided by Dr. J. Neefjes) and anti-HLA-
DR (clone LN3; Signet Laboratories Inc., Dedham, MA).
For Bax, cIAP2 and HLA-A the staining procedure was
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123done as described previously [5, 11, 12]. For ARC and
HLA-DR we used the following protocol: tissues had been
deparafﬁnised and endogenous peroxidise activity had been
blocked by 0.3% hydrogen peroxide in methanol for
30 min. Antigen retrieval was performed by boiling for
10 min in 0.01 M citrate buffer (pH 6.0). Subsequently,
sections were preincubated for 30 min with 20% normal
goat serum in PBS/1% BSA. After overnight incubation
with the primary antibody sections were incubated for 1 h
with biotinylated goat-anti-mouse or goat-anti-rabbit
(1:200, DakoCytomation, Glostrup, Denmark) followed by
incubation with streptavidin complexed with biotinylated
peroxidase (DakoCytomation), and developed in 3,3-di-
amino-benzidine (DakoCytomation). Finally, sections were
counterstained with Mayer’s haematoxylin. As negative
control, the primary antibody in PBS/1% BSA was re-
placed by PBS alone. The results presented for each anti-
body are based on the analysis of tissues from at least 4
individuals per group.
Results
Genes differentially expressed in low- and high-
apoptotic rectal tumors
Previously we have reported that rectal cancer patients with
high levels of apoptosis in their tumors develop less fre-
quent local recurrences than patients with lower levels of
apoptosis [2]. Because this high level of apoptosis occurred
in the absence of neo-adjuvant treatment, it is thought to be
an intrinsic characteristic of the tumors, suggesting regu-
lation at the level of gene expression. To identify genes of
which the expression correlates with the level of intrinsic
apoptosis in vivo, 47 non-irradiated rectal tumors with
known apoptotic phenotype were analyzed by oligo
microarray technology. We selected 24 low-apoptotic and
23 high-apoptotic tumors (< 5 and > 25 apoptotic cells/
mm
2 tumor epithelium, respectively) with equal distribu-
tions of TNM stages, differentiation status and amounts of
stromal tissue. Comparing these low- and high-apoptotic
tumors, we identiﬁed 85 oligos representing 60 annotated
genes differentially expressed at statistically signiﬁcant
levels (Supplementary Table 1). Several genes code for
proteins that have been described to play a role in apoptosis
regulation, such as ARC [13–15], DDAH2 [16], STC2 [17]
and Steﬁn A [18]. GO terms were used to classify the genes
with known functions into biological processes, and
showed that most of the identiﬁed genes code for proteins
that are associated with antigen processing and presenta-
tion, metabolism, proliferation and transcription (Fig. 1).
Despite the clear differences in apoptotic levels between
the two tumor groups, which also correlate with different
clinical outcomes, we observed a relatively minor change
in expression of the identiﬁed oligos (Supplementary Table
1). This observation could imply that intrinsic apoptosis is
regulated in a gene-expression independent manner or that
genetic differences are obscured by the fact that multiple
subgroups exist within the high- or low-apoptotic tumors.
To analyze whether different subgroups exist, unsupervised
clustering of the tumors based on the 85 identiﬁed oligos
was performed (Fig. 2A). As expected, a high concordance
of clustering was observed for the apoptotic phenotype;
most low-apoptotic tumors were clustered to the left and
most high-apoptotic tumors were clustered to the right side
of the tree. Interestingly, two subgroups were visible within
the group of high-apoptotic tumors. Further analysis con-
ﬁrmed this observation and revealed that unsupervised
clustering of only the high-apoptotic tumors divided these
tumors into two clear groups, denoted clusters A and B
(Fig. 2B).
The existence of two distinct high-apoptotic clusters
suggests that two different gene expression proﬁles were
related with the process of apoptosis in vivo. Therefore, we
determined the differences between clusters A and B by
comparing the microarray data of the two subclusters. This
analysis revealed 255 oligos that were differentially ex-
pressed at signiﬁcant levels (Supplementary Table 2). A
high amount of these oligos code for proteins involved with
the immune system (defense response, immune response
and antigen processing and presentation). GOTM analysis
was done to compare the list of genes represented by the
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Fig. 1 Clustering of genes in biological processes. Genes represented
by the 86 identiﬁed oligos were clustered in biological categories
according to their GO term
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123255 discriminating oligos with all oligos on the array of
which the expression proﬁle could be evaluated. These
immune-related biological processes were indeed signiﬁ-
cantly enriched in the list of genes that were differentially
expressed. Interestingly, the immune-related genes were all
highly expressed in cluster B. During tumor selection, we
excluded differences in amounts of stroma between the
high- and low-apoptotic tumors. But since we used mac-
rodissected samples, the immune-related expression proﬁle
of cluster B could result from difference in the amount of
stromal cells between clusters A and B. We therefore re-
evaluated HE-stained slides of the macrodissected tumors
and found no substantial differences in morphology or in
the amount of stroma between the tumor clusters (Fig. 3).
These data exclude that the immune-related gene expres-
sion proﬁle of cluster B results from simply more stromal
cells.
The gene expression data therefore indicate that differ-
ent sets of genes are involved in the regulation of apoptosis
in clusters A and B.
High-apoptotic phenotype of Cluster A
Five of the genes differentially expressed in the high-
apoptotic clusters are related to cell death on basis of their
GO term (Supplementary Table 2). Two of these have been
described to play an important role in the mitochondrial
pathway of apoptosis: BAX and cIAP2. We ﬁrst focussed
our study on these genes and validated their expression
levels by qPCR. The qPCR data correlated signiﬁcantly
with the microarray data (Table 1) and conﬁrmed higher
expression of BAX and lower expression of cIAP2 in
cluster A compared with cluster B (Fig. 4A).
In our previous analyses comparing all high-apoptotic
tumorswiththelow-apoptotictumors,BAXandcIAP2were
on average expressed at similar levels (fold difference be-
tween the high- and low-apoptotic tumors was 0.9 for BAX
and 1.1 for cIAP2, both not statistically signiﬁcant). Inter-
estingly, the high-apoptotic tumors can be divided into two
separateclustersofwhichclusterAshowedhigherBAXand
lower cIAP2 expression when compared with cluster B. In
addition, we observed signiﬁcant lower cIAP2 expression
levels and a trend towards higher BAX expression in the
high-apoptotic tumors of cluster A than in the low-apoptotic
tumors. These data strengthen the signiﬁcance of dividing
the high-apoptotic tumors into two subgroups.
To further analyze the high-apoptotic phenotype of
cluster A, the microarray data of these tumors were com-
pared with the low-apoptotic tumors. Surprisingly, this
analysis revealed only ﬁve oligos, indicating a low number
of differentially expressed genes (Supplementary Table 3).
Genetic differences between these two groups of tumors
are thus very small. This might imply an apoptosis regu-
lation independent of gene expression levels. Nonetheless,
one of the identiﬁed oligos represented the anti-apoptotic
protein ARC. This protein was reported to bind Bax, and to
prevent the release of cytochrome c [13]. The microarray
data show that ARC was expressed at signiﬁcantly lower
levels in the high-apoptotic cluster A when compared to the
low-apoptotic tumors. Validation of the microarray data by
qPCR conﬁrmed the lower ARC expression in the tumors
of cluster A as compared to the low-apoptotic tumors
(Fig. 4A).
The differential expression of BAX, cIAP2 and ARC
between the tumor clusters was evaluated on protein level
by immunohistochemistry. Differences in staining intensi-
ties conﬁrmed the mRNA data; tumors belonging to cluster
A stained Bax with higher and cIAP2 with lower intensities
then cluster B and low-apoptotic tumors. ARC was also
lower expression in the high-apoptotic cluster A and B
A
o g i l O1
o g i l O 85
B
e t s u l CA   r e t s u l CB   r
Fig. 2 Unsupervised clustering of low- and high-apoptotic tumors.
(A) Unsupervised clustering of all tumors based on the microarray
data of the 86 discriminating oligos. Each column represents a tumor
sample and each row represents an oligo (listed in Supplementary
Table 1 in same order as represented in this clustering); green
indicates a lower and red indicates a higher presence of the oligo in
the tumors compared with the reference. The tree above indicates the
correlation between tumors; a black line for the low-apoptotic tumors,
and a colored line for the high-apoptotic tumors. (B) Unsupervised
clustering of only the high-apoptotic tumors separated the tumors into
two subgroups, denoted as cluster A and cluster B. Cluster A is
compiled of the tumors which were indicated in orange, and cluster B
of the tumors which were indiacted in red in (A). Note that the tumors
of cluster A are close to the low-apoptotic tumors
Apoptosis (2007) 12:1671–1680 1675
123when compared with the low-apoptotic tumors (Fig. 4B
and Supplementary Fig. 1).
Overall, the high-apoptotic phenotype of the tumors
belonging to cluster A might be explained by gene
expression-independent regulation, or might be the result
of lower expression of the anti-apoptotic ARC and cIAP2
in combination with a slightly higher expression of the pro-
apoptotic BAX.
High-apoptotic phenotype of cluster B
The high-apoptotic tumors of cluster B formed a separate
group in the unsupervised clustering analysis (Fig. 2A),
suggesting a distinct gene expression proﬁle. By comparing
the gene expression proﬁles of these high-apoptotic tumors
with the low-apoptotic tumors, we identiﬁed 322 oligos,
representing 217 annotated genes differentially expressed
(Supplementary Table 4). Interestingly, 37% of the oligos
had a 2-fold change or more in expression, indicating a
substantial difference in genetic background of these
groups of tumors.
GOTM analysis with this set of 322 oligos revealed a
signiﬁcant enrichment of immune-related categories. These
categories were previously identiﬁed when cluster B was
compared with cluster A, suggesting that these categories
are speciﬁc for the high-apoptotic tumors of cluster B.
We focussed our study on the genes with low p-values
and high fold-changes in their expression. A large pro-
portion of these genes coded for immune-related proteins,
such as chemokines and HLA class II and class I proteins.
The expressions of the chemokines CXCL9, CCL4 and
CCL18 and the antigen presenting-related proteins HLA-
DR, HLA-A and TAP1 were validated by qPCR. The
qPCR data correlated signiﬁcantly with the microarray data
(Table 1) and conﬁrmed the high expression of these genes
in the high-apoptotic tumors of cluster B when compared
with the low-apoptotic tumors, and also with the high-
apoptotic tumors of cluster A (Fig. 5A). Immunohisto-
chemistry for HLA class I and HLA class II proteins re-
vealed no difference in staining intensity of tumor cells for
HLA-A. Intriguingly, 70% of the tumors belonging to
cluster B showed positive staining for HLA-DR in epi-
thelial tumor cells, whereas low-apoptotic or cluster A
tumors stained negative for HLA-DR on the epithelial tu-
mor cells (Fig. 5B and Supplementary Fig. 2). Next to
HLA-DR, several other interferon-gamma-inducible genes
showed high gene expression in cluster B. Since interferon-
gamma is produced and secreted by activated immune
cells, these data suggest that the high-apoptotic phenotype
of cluster B, in contrast to cluster A, is most likely the
result of an immunologic control of these tumors.
Fig. 3 Representative photomicrographs of HE-stained tumor tis-
sues. Frozen tissues are shown in the upper panel, corresponding
parafﬁn-embedded tissues in the lower panel. For each cluster (low-
apoptotic, high-apoptotic cluster A, high-apoptotic cluster B) two
representative photomicrographs are shown
Table 1 Correlation between qPCR and microarray data
Gene Correlation p-value
BAX 0.61 < 0.001
cIAP2 0.58 0.01
ARC 0.69 < 0.001
CXCL9 0.72 < 0.001
CCL4 0.91 < 0.001
CCL18 0.94 < 0.001
HLA-DR 0.92 < 0.001
HLA-A 0.70 < 0.001
TAP1 0.69 < 0.001
Pearson correlation coefﬁcients were calculated with log2-trans-
formed qPCR and microarray data
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In this study we describe the identiﬁcation of genes which
are differentially expressed in low- versus high-apoptotic
rectal tumors. Since the rectal cancer patients were treated
by surgery only, the identiﬁed genes are related to the tu-
mor-intrinsic level of apoptosis in vivo, previously de-
scribed to predict local recurrences [1, 2]. Importantly,
unsupervised clustering analysis identiﬁed two clusters of
high-apoptotic tumors, suggesting two distinct mechanisms
regulating apoptosis in vivo. We therefore analyzed these
two clusters of high-apoptotic tumors separately.
The differences in gene expression between one of the
high-apoptotic clusters (cluster A) and the low-apoptotic
tumors were subtle; these high-apoptotic tumors clustered
close to the low-apoptotic tumors in the unsupervised
clustering and a very low amount of genes were identiﬁed
as differentially expressed at statistically signiﬁcant levels.
The high-apoptotic phenotype of these tumors might
therefore, at least to some extent, be explained by gene-
expression independent regulation, such as distinct locali-
zation of proteins (e.g. mitochondria versus cytosol), and
inactivation or activation of proteins via phosphorylation
(Bad) or cleavage (caspases). Another explanation for the
low amount of differentially expressed genes can be the
fact that we used strict cut-off values for signiﬁcance for
each single oligo in order to minimize the number of false-
positive genes. After correcting for multiple hypotheses
testing, hardly any individual gene meets the threshold for
statistical signiﬁcance when the genetic differences are
modest relative to the background noise. In that case, dif-
ferences in expression of individual genes might not reach
signiﬁcant levels, but a combination of small differences in
expression of genes belonging to the same pathway can
have profound biological consequences [19].
More in-depth analyses on the known apoptotic regu-
lators BAX, ARC and cIAP2 revealed small differences in
mRNA expression among the three tumor groups, which
were conﬁrmed on protein level. The pro-apoptotic protein
Bax plays an important role in the permeabilization of the
mitochondrial membrane, leading to release of cytochrome
c into the cytosol. Cytosolic cytochrome c, together with
APAF-1, activates caspase-9 and subsequently caspase-3.
The highest Bax expression was observed in cluster A of
the intrinsically high-apoptotic tumors. In accordance with
our results, recent clinical studies have shown that high
Bax protein expression (in pretreatment biopsies) was
associated with improved local control for rectal cancer
patients [4, 5], or improved survival for colorectal carci-
noma patients treated by surgery only [20]. Furthermore,
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123in vitro experiments have shown a role for Bax in the
apoptotic response of colorectal cancer cells to multiple
death stimuli [21, 22]. Tumors with high Bax expression
in vivo might therefore be more susceptible to apoptotic
triggers. In addition, the high-apoptotic tumors of cluster A
demonstrated a relatively low expression of the anti-
apoptotic ARC and cIAP2. ARC exerts its anti-apoptotic
function by interfering with Bax. In doing so, it prevents
mitochondrial permeabilization and the release of cyto-
chrome c [13]. The anti-apoptotic cIAP2 belongs to the
family of Inhibitor of apoptotis proteins (IAPs) that is
suggested to prevent apoptosis (at least partially) due to
binding to caspases, thereby inhibiting the caspase activity
[23, 24]. The cumulative effects of a slight higher
expression of Bax and lower expression of ARC and cIAP2
might thus be responsible for the high-apoptotic phenotype
of the tumors belonging to cluster A.
Intriguingly, the high-apoptotic tumors belonging to
cluster B expressed high levels of genes that code for
proteins involved in the immune response. Several publi-
cations showed that important signaling events occur
between tumor cells and the surrounding stromal and
inﬁltrating cells [25–27]. Microdissection of only tumor
epithelial cells could thus lead to substantial loss of
information regarding these mechanisms. We recently
published that macrodissection provides more reliable data
for the expression of tumor epithelial genes than laser
microdissection [28]. For those reasons, we used macro-
dissected samples, containing stromal components. This
approach resulted in the identiﬁcation of a high expression
of immune-related genes in the tumors of cluster B. This
high expression in cluster B is probably not an effect of
more stroma. We previously published that the contribution
of stromal mRNA to the total amount of mRNA isolated
from macrodissected tumors is minor [28], and we did not
observe large differences in the amount of stroma between
the tumors. In agreement, immunohistochemistry using
HLA-DR, Bax and cIAP2 conﬁrms that the differential
expression results from epithelial tumor cells. Although the
amounts of stroma were equally distributed, the composi-
tion of the stromal compartment can vary between the
clusters. In mouse models, induced expression of HLA-DR
in epithelial tumor cells enhances the inﬁltration of den-
dritic cells and anti-tumor T-cell responses [29, 30]. The
high expression of chemokines in cluster B tumors might
thus result from tumor inﬁltrating immune cells, pointing to
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123a phenotypic difference between the clusters. The obser-
vation that multiple interferon-gamma-induced genes were
higher expressed in these high-apoptotic tumors (e.g.
TRIM22, IFI30, STAT1, IRF1, INDO) suggest that these
tumors indeed mount an immune response, leading to
interferon secretion and induction of interferon-responsive
genes. Interferon-gamma can induce apoptosis in tumor
cells directly, and also via enhancement of the immune
response [31]. Our data therefore strongly suggest that
these patients with intrinsically high-apoptotic tumors
mount an immune response towards the tumor cells,
thereby controlling tumor recurrences. Pages and cowork-
ers recently published a role for the adaptive immune re-
sponse in preventing recurrences in colorectal cancer
patients [32, 33]. Moreover, we previously published that
the amount of intratumoral macrophages, NK- and T-cells
correlated with a reduced local recurrence rates in rectal
cancer patients [34], again indicating an immune-mediated
control of rectal cancer.
Conclusion
Microarray analysis on intrinsically low- and high-apop-
totic tumors identiﬁed two separate groups of high-apop-
totic rectal tumors. One group demonstrated subtle
differences in expression of known pro- and anti-apoptotic
proteins involved in the mitochondrial pathway. Because
the expression differences are small, gene independent
regulation of apoptosis might play a role as well. The other
group of high-apoptotic tumors showed high expression of
immune-related genes, suggesting a host’s immune re-
sponse towards the tumor cells. Since rectal cancer patients
with intrinsically high-apoptotic tumors have a better
prognosis, this information may provide insight in the
development of novel therapeutic regimens.
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